Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Capravirine · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| capravirine | DRUG | - |
| Kaletra | DRUG | - |
| 2 NRTIs | DRUG | - |
Inclusion Criteria: * HIV-infected male or female at least 18 years of age * HIV RNA level \>1000 copies/mL at screening * Subject has failed regimens that included at least 1 protease inhibitor but not more than 3 protease inhibitors, at least 1 nonnucleoside reverse transcriptase inhibitor, and l...
Capravirine is an investigational small molecule being developed for the treatment of HIV Infections and Human Immunodeficiency Virus. It is intended for use in HIV infected patients, including those who have failed an initial NNRTI containing regimen. The drug is currently in Phase 2 clinical development.
Capravirine is being developed by Pfizer, Inc., which is publicly traded under the ticker symbol PFE. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with HIV infections.
Capravirine is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials to determine its safety and effectiveness for treating HIV infections.
Capravirine has been studied in two completed Phase 2 clinical trials. One trial, NCT00051844, evaluated Capravirine in combination with Viracept and two NRTIs in HIV infected patients who failed an initial NNRTI containing regimen. Another trial, NCT00052117, studied a four-drug combination treatment in HIV infected subjects failing therapy.
Capravirine is also known as AG1549. The clinical trial NCT00051844 refers to Capravirine as AG1549 in its title, confirming that these names refer to the same investigational drug being developed by Pfizer for the treatment of HIV infections.